Preface |
|
v | |
|
|
vii | |
Trade Names and Their Corresponding USANs |
|
xi | |
Acronyms and Abbreviations |
|
xiii | |
|
Antithrombotics: Ticlopidine (Ticlid®) and Clopidogrel (Plavix®) |
|
|
1 | (10) |
|
|
1 | (2) |
|
|
3 | (1) |
|
|
4 | (5) |
|
|
9 | (2) |
|
Anti-inflammatory Cyclooxygenase-2 Selective Inhibitors: Celecoxib (Celebrex®) and Rofecoxib (Vioxx®) |
|
|
11 | (10) |
|
|
11 | (2) |
|
|
13 | (1) |
|
|
14 | (5) |
|
|
19 | (2) |
|
H+/K+-ATPase Inhibitors: Esomeprazole (Nexium®) |
|
|
21 | (8) |
|
|
21 | (2) |
|
Synthesis of esomeprazole |
|
|
23 | (4) |
|
|
24 | (1) |
|
Asymmetric oxidation of the sulfide |
|
|
25 | (1) |
|
|
26 | (1) |
|
|
27 | (2) |
|
Protein-tyrosine Kinase Inhibitors: Imatinib (Gleevec®) and Gefitinib (Iressa®) |
|
|
29 | (10) |
|
|
29 | (3) |
|
Synthesis of imatinib mesylate |
|
|
32 | (2) |
|
|
34 | (1) |
|
|
35 | (2) |
|
|
37 | (2) |
|
Non-sedating Antihistamines |
|
|
39 | (16) |
|
|
39 | (1) |
|
Synthesis of loratadine and desloratadine |
|
|
40 | (3) |
|
Synthesis of fexofenadine |
|
|
43 | (5) |
|
|
48 | (4) |
|
|
52 | (3) |
|
Cosmeceuticals: Isotretinoin (Accutane®), Tazarotene (Tazorac®), Minoxidil (Rogaine®), and Finasteride (Propecia®) |
|
|
55 | (20) |
|
|
56 | (3) |
|
Introduction to isotretinoin |
|
|
56 | (1) |
|
Synthesis of isotretinoin |
|
|
57 | (2) |
|
|
59 | (3) |
|
Introduction to tazarotene |
|
|
59 | (2) |
|
|
61 | (1) |
|
|
62 | (4) |
|
Introduction to minoxidil |
|
|
62 | (1) |
|
|
63 | (3) |
|
|
66 | (5) |
|
Introduction to finasteride |
|
|
66 | (1) |
|
|
67 | (4) |
|
|
71 | (4) |
|
Antibacterials: Ciprofloxacin (Cipro®) and Linezolid (Zyvox®) |
|
|
75 | (14) |
|
|
76 | (7) |
|
Introduction to ciprofloxacin |
|
|
76 | (3) |
|
Synthesis of ciprofloxacin |
|
|
79 | (4) |
|
|
83 | (3) |
|
Introduction to linezolid |
|
|
83 | (1) |
|
|
84 | (2) |
|
|
86 | (3) |
|
|
89 | (24) |
|
|
89 | (4) |
|
|
93 | (3) |
|
|
96 | (3) |
|
Synthesis of quetiapine fumarate |
|
|
99 | (2) |
|
|
101 | (6) |
|
Synthesis of aripiprazole |
|
|
107 | (1) |
|
|
108 | (5) |
|
Atorvastatin Calcium (Lipitor®) |
|
|
113 | (12) |
|
|
113 | (2) |
|
Synthesis of racemic atorvastatin |
|
|
115 | (3) |
|
Enantioselective syntheses of atorvastatin calcium |
|
|
118 | (6) |
|
|
124 | (1) |
|
|
125 | (24) |
|
|
125 | (3) |
|
Synthesis of fluoxetine hydrochloride |
|
|
128 | (5) |
|
Synthesis of sertraline hydrochloride |
|
|
133 | (5) |
|
Synthesis of paroxetine hydrochloride |
|
|
138 | (7) |
|
|
145 | (4) |
|
Anti-obesity: Orlistat (Xenical®) |
|
|
149 | (12) |
|
|
149 | (3) |
|
|
152 | (6) |
|
|
158 | (3) |
|
|
161 | (28) |
|
|
162 | (1) |
|
|
163 | (5) |
|
Synthesis of zolmitriptan |
|
|
168 | (3) |
|
|
171 | (3) |
|
|
174 | (3) |
|
|
177 | (3) |
|
Synthesis of frovatriptan |
|
|
180 | (3) |
|
|
183 | (3) |
|
|
186 | (3) |
|
PDE 5 Inhibitors for Erectile Dysfunction: Sildenafil (Viagra®), Vardenafil (Levitra®), and Tadalafil (Cialis®) |
|
|
189 | (12) |
|
|
189 | (2) |
|
Discovery and synthesis of sildenafil |
|
|
191 | (4) |
|
|
195 | (2) |
|
|
197 | (2) |
|
|
199 | (2) |
|
|
201 | (13) |
|
|
201 | (2) |
|
Synthesis of fluticasone propionate |
|
|
203 | (2) |
|
Synthesis of salmeterol xinafoate |
|
|
205 | (5) |
|
Synthesis of montelukast sodium |
|
|
210 | (2) |
|
|
212 | (2) |
Index |
|
214 | |